Search - tctmd.com

Displaying 81 - 100 of 703

Sort: Relevancy | Date

Presentation THT 2025

When to Use Devices the Recude Renal Vein Pressure

Presenter: Liviu Klein

February 12, 2025

Presentation THT Abstracts 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT 2025

Renal Dysfunction as a Primary Mechanism of Symptoms in (Most) Patients With HFpEF

Presenter: Jeffrey Testani

February 11, 2025

Presentation Miami Valves 2025

Initial Experience with the Symplicity Spiral Catheter for Renal Artery Denervation in the Dominican Republic

Presenter: Marcos Domínguez Vargas

January 30, 2025

Presentation TCT 2024

TCT 329: Pharmacokinetics of 14C-Labeled Zalunfiban (RUC-4) Suggests That No Dose Adjustment Is Necessary for Impaired Renal Function

Presenter: Sem Rikken

October 30, 2024

Presentation TCT 2024

TCT 707: Percutaneous Renal Denervation in the Management of Kidney-Related Pain Syndromes: A Case Series

Presenter: Kari Saville

October 30, 2024

Presentation TCT 2024

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

Presenter: Raymond Townsend

October 29, 2024

Presentation TCT 2024

Debate Con: RDN Will Ultimately Be a Niche Therapy

Presenter: Andrew Sharp

October 29, 2024

Presentation TCT 2024

Debate Con: Predictors of Efficacy are Sorely Needed in the RDN Space!

Presenter: Eric Secemsky

October 29, 2024

Presentation TCT 2024

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

Presenter: Michael Weber

October 29, 2024

Presentation TCT 2024

How to Set Up Your RDN Hypertension Program: Team Members and Patient Flow

Presenter: Michael Bloch

October 29, 2024

Presentation TCT 2024

What Evaluation is Required for Patient Selection for RDN?

Presenter: Naomi Fisher

October 29, 2024

Presentation TCT 2024

TCT 597: Evaluation of Renal Functional Reserve in Patients With Coronary Microvascular Dysfunction and Preserved Renal Function

Presenter: Kyriakos Dimitriadis

October 29, 2024

Presentation TCT 2024

TCT 823: Association Between Sodium-Glucose Co-Transporter 2 Inhibitor Use and Renal Function After Transcatheter Aortic Valve Replacement: A Retrospective Matched Cohort Analysis

Presenter: Pamela Ropski

October 29, 2024

Presentation TCT 2024

TCT 824: TAVI on Coronary Guidewires: Free-Contrast Technique in Patients With Moderate to Severe Renal Impairment

Presenter: Iulia Tustiu

October 29, 2024

Presentation TCT 2024

Multiorgan Denervation in Hypertension and Beyond – From Renal to Hepatic

Presenter: Raven Voora

October 28, 2024

Presentation TCT 2024

Alternative Renal Denervation Devices – From Ablative Solutions to Verve

Presenter: Michael Weber

October 28, 2024

Presentation TCT 2024

Ultrasound Renal Denervation in Hypertension – From Paradise to Sonivie

Presenter: Naomi Fisher

October 28, 2024

Presentation TCT 2024

Radiofrequency Renal Denervation in Hypertension – From Symplicity to Iberis HTN

Presenter: Lucas Lauder

October 28, 2024

Advertisement

When to Use Devices the Recude Renal Vein Pressure

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Renal Dysfunction as a Primary Mechanism of Symptoms in (Most) Patients With HFpEF

Initial Experience with the Symplicity Spiral Catheter for Renal Artery Denervation in the Dominican Republic

TCT 329: Pharmacokinetics of 14C-Labeled Zalunfiban (RUC-4) Suggests That No Dose Adjustment Is Necessary for Impaired Renal Function

TCT 707: Percutaneous Renal Denervation in the Management of Kidney-Related Pain Syndromes: A Case Series

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

Debate Con: RDN Will Ultimately Be a Niche Therapy

Debate Con: Predictors of Efficacy are Sorely Needed in the RDN Space!

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

How to Set Up Your RDN Hypertension Program: Team Members and Patient Flow

What Evaluation is Required for Patient Selection for RDN?

TCT 597: Evaluation of Renal Functional Reserve in Patients With Coronary Microvascular Dysfunction and Preserved Renal Function

TCT 823: Association Between Sodium-Glucose Co-Transporter 2 Inhibitor Use and Renal Function After Transcatheter Aortic Valve Replacement: A Retrospective Matched Cohort Analysis

TCT 824: TAVI on Coronary Guidewires: Free-Contrast Technique in Patients With Moderate to Severe Renal Impairment

Multiorgan Denervation in Hypertension and Beyond – From Renal to Hepatic

Alternative Renal Denervation Devices – From Ablative Solutions to Verve

Ultrasound Renal Denervation in Hypertension – From Paradise to Sonivie

Radiofrequency Renal Denervation in Hypertension – From Symplicity to Iberis HTN

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content